Nature-Throid
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
832 recalls, newest first
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Lack of CGMPs:
Sub-Potent Drug: Out of specification test results for potency (below specification).
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
CGMP deviations; there is a possibility that some bottles in these lots may have the active ingredient above and/or below specification limits.
Failed Dissolution Specifications
CGMP Deviations
CGMP Deviations
GMP Deviations: Potential to contain 1-propanol.
GMP Deviations: Potential to contain 1-propanol.
cGMP Deviations
cGMP Deviations
Microbial Contamination of Non-Sterile Products: FDA laboratory analysis found product to be contaminated with various microorganisms including Enterobacter cloacae, Cronobacter sakazakii, Cronobacter dublinensis, among others.
Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.
Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.
Marketed without an Approved NDA/ANDA; product labeled to contain 0.56% methanol making it an unapproved new drug
Marketed without an Approved NDA/ANDA; product labeled to contain 0.56% methanol making it an unapproved new drug
Marketed without an Approved NDA/ANDA; product labeled to contain 0.56% methanol making it an unapproved new drug
Marketed without an Approved NDA/ANDA; product labeled to contain 0.56% methanol making it an unapproved new drug
Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
CGMP Deviations: All other lots are being recalled because they were manufactured under the same conditions as the product lots found to contain methanol.
Chemical Contamination: FDA analysis found the product contains methanol, additionally it is sub-potent for ethanol content.